Drug Name | Pathway ID | Pathway name | P-value | No. of gene members | UniProt AC | Gene name | Detail of Coexpression | |
---|
Bexarotene | hsa00190 | Oxidative phosphorylation | 8.71E-03 | 3 | Q16718, Q13488, O14521 | NDUFA5, TCIRG1, SDHD | More | | Bexarotene | hsa00500 | Starch and sucrose metabolism | 1.42E-03 | 3 | O43451, P46976, P06737 | MGAM, GYG1, PYGL | More | | Bexarotene | hsa00512 | Mucin type O-glycan biosynthesis | 3.78E-02 | 2 | O95395, Q8N4A0 | GCNT3, GALNT4 | More | | Bexarotene | hsa00520 | Amino sugar and nucleotide sugar metabolism | 7.87E-03 | 3 | Q16222, Q9Y223, P06865 | UAP1, GNE, HEXA | More | | Bexarotene | hsa00603 | Glycosphingolipid biosynthesis - globo and isoglobo series | 4.30E-03 | 2 | P06865, O75752 | HEXA, B3GALNT1 | More | | Bexarotene | hsa00630 | Glyoxylate and dicarboxylate metabolism | 7.59E-03 | 2 | P40925, P15104 | MDH1, GLUL | More | | Bexarotene | hsa00730 | Thiamine metabolism | 4.07E-02 | 2 | P05186, P24666 | ALPL, ACP1 | More | | Bexarotene | hsa00920 | Sulfur metabolism | 3.18E-02 | 1 | Q16762 | TST | More | | Bexarotene | hsa00970 | Aminoacyl-tRNA biosynthesis | 2.76E-03 | 2 | O95363, Q15046 | FARS2, KARS | More | | Bexarotene | hsa01100 | Metabolic pathways | 4.43E-02 | 23 | Q9NR34, P05089, P32320, P22748, P55809, P06280, Q16875, O43286, O43451, P05186, P24666, Q9HCC0, P33121, P57054, Q9UNP4, Q9BX95, P32321, Q9BPW9, O75911, Q9UHY7, P43490, P46976, P06737 | MAN1C1, ARG1, CDA, CA4, OXCT1, GLA, PFKFB3, B4GALT5, MGAM, ALPL, ACP1, MCCC2, ACSL1, PIGP, ST3GAL5, SGPP1, DCTD, DHRS9, DHRS3, ENOPH1, PBEF1, GYG1, PYGL | More | | Bexarotene | hsa01240 | Biosynthesis of cofactors | 2.52E-02 | 2 | Q9BQB6, P14550 | VKORC1, AKR1A1 | More | | Bexarotene | hsa01524 | Platinum drug resistance | 1.79E-02 | 2 | O15392, P11388 | BIRC5, TOP2A | More | | Bexarotene | hsa03013 | RNA transport | 2.99E-02 | 4 | P38919, P37198, P35658, P55884 | EIF4A3, NUP62, NUP214, EIF3B | More | | Bexarotene | hsa03018 | RNA degradation | 5.00E-02 | 1 | Q9NQT4 | EXOSC5 | More | | Bexarotene | hsa03020 | RNA polymerase | 9.80E-05 | 2 | Q9GZM3, P52435 | POLR2J2, POLR2J | More | | Bexarotene | hsa03040 | Spliceosome | 1.28E-05 | 13 | O43143, O60508, P08579, P26368, Q13595, Q07955, Q01130, P84103, Q13243, P11142, Q9Y2W2, O43447, O75643 | DHX15, CDC40, SNRPB2, U2AF2, TRA2A, SFRS1, SFRS2, SFRS3, SFRS5, HSPA8, WBP11, PPIH, ASCC3L1 | More | | Bexarotene | hsa03050 | Proteasome | 3.05E-02 | 1 | P55036 | PSMD4 | More | | Bexarotene | hsa03060 | Protein export | 3.28E-02 | 2 | Q15070, O76094 | OXA1L, SRP72 | More | | Bexarotene | hsa03320 | PPAR signaling pathway | 3.78E-02 | 2 | Q6PCB7, Q9UNU6 | SLC27A1, CYP8B1 | More | | Bexarotene | hsa03410 | Base excision repair | 2.52E-02 | 2 | P49005, P29372 | POLD2, MPG | More | | Bexarotene | hsa04010 | MAPK signaling pathway | 1.53E-02 | 2 | Q9H2K8, Q12933 | TAOK3, TRAF2 | More | | Bexarotene | hsa04012 | ErbB signaling pathway | 3.15E-02 | 3 | P16333, P19174, P01106 | NCK1, PLCG1, MYC | More | | Bexarotene | hsa04014 | Ras signaling pathway | 2.36E-02 | 8 | P42338, P20827, P49767, Q13009, Q7LDG7, P63218, P50151, P19174 | PIK3CB, EFNA1, VEGFC, TIAM1, RASGRP2, GNG5, GNG10, PLCG1 | More | | Bexarotene | hsa04015 | Rap1 signaling pathway | 2.69E-03 | 11 | P20827, P49767, Q96FS4, P11215, P25116, Q8TEU7, Q13009, Q7LDG7, P42338, P08514, P19174 | EFNA1, VEGFC, SIPA1, ITGAM, F2R, RAPGEF6, TIAM1, RASGRP2, PIK3CB, ITGA2B, PLCG1 | More | | Bexarotene | hsa04061 | Viral protein interaction with cytokine and cytokine receptor | 4.48E-02 | 5 | P09341, P19875, P25024, P25025, P14784 | CXCL1, CXCL2, CXCR1, CXCR2, IL2RB | More | | Bexarotene | hsa04062 | Chemokine signaling pathway | 8.58E-05 | 15 | P25024, P25025, P09341, P19875, P09769, P07948, P42338, P19174, P63218, P50151, P43250, P49407, Q7LDG7, Q13009, Q8WYR1 | CXCR1, CXCR2, CXCL1, CXCL2, FGR, LYN, PIK3CB, PLCG1, GNG5, GNG10, GRK6, ARRB1, RASGRP2, TIAM1, PIK3R5 | More | | Bexarotene | hsa04064 | NF-kappa B signaling pathway | 2.43E-04 | 17 | P10415, Q13489, O00463, P14778, P29965, P19174, Q04759, Q9UDY8, Q13077, Q16548, P06239, Q8WV28, Q13315, P24522, P09341, P19875, Q06643 | BCL2, BIRC3, TRAF5, IL1R1, CD40LG, PLCG1, PRKCQ, MALT1, TRAF1, BCL2A1, LCK, BLNK, ATM, GADD45A, CXCL1, CXCL2, LTB | More | | Bexarotene | hsa04070 | Phosphatidylinositol signaling system | 3.47E-02 | 4 | P0DP23, Q14643, P23743, P17252 | CALM1, ITPR1, DGKA, PRKCA | More | | Bexarotene | hsa04071 | Sphingolipid signaling pathway | 1.48E-05 | 10 | P17252, P21453, Q9H228, P01375, Q13362, Q9BX95, Q16539, P10415, Q12933, Q02156 | PRKCA, S1PR1, EDG8, TNF, PPP2R5C, SGPP1, MAPK14, BCL2, TRAF2, PRKCE | More | | Bexarotene | hsa04072 | Phospholipase D signaling pathway | 4.48E-02 | 5 | P42338, P43657, P25024, P25025, P19174 | PIK3CB, P2RY5, CXCR1, CXCR2, PLCG1 | More | | Bexarotene | hsa04110 | Cell cycle | 1.44E-02 | 7 | P06493, O75293, P30304, P33981, P42773, P01106, Q13547 | CDK1, GADD45B, CDC25A, TTK, CDKN2C, MYC, HDAC1 | More | | Bexarotene | hsa04114 | Oocyte meiosis | 1.62E-04 | 5 | Q9Y6D9, P51812, Q02750, P16298, Q17RY0 | MAD1L1, RPS6KA3, MAP2K1, PPP3CB, CPEB4 | More | | Bexarotene | hsa04122 | Sulfur relay system | 3.18E-02 | 1 | Q16762 | TST | More | | Bexarotene | hsa04145 | Phagosome | 1.21E-04 | 10 | O75015, Q15080, P14598, Q13509, P68371, Q13488, P05164, O60603, P35443, P13765 | FCGR3B, NCF4, NCF1, TUBB3, TUBB2C, TCIRG1, MPO, TLR2, THBS4, HLA-DOB | More | | Bexarotene | hsa04150 | mTOR signaling pathway | 3.60E-02 | 3 | Q02750, Q9NQL2, P51812 | MAP2K1, RRAGD, RPS6KA3 | More | | Bexarotene | hsa04151 | PI3K-Akt signaling pathway | 5.33E-03 | 20 | P42338, P43657, P25116, P20827, P49767, Q13362, P08238, Q8WYR1, P62873, P63218, P50151, P16144, O15335, Q13751, O60603, P14784, P01568, P10415, P17252, P30281 | PIK3CB, P2RY5, F2R, EFNA1, VEGFC, PPP2R5C, HSP90AB1, PIK3R5, GNB1, GNG5, GNG10, ITGB4, CHAD, LAMB3, TLR2, IL2RB, IFNA21, BCL2, PRKCA, CCND3 | More | | Bexarotene | hsa04213 | Longevity regulating pathway - multiple species | 3.85E-02 | 4 | P42338, Q9Y4H2, P11142, Q13547 | PIK3CB, IRS2, HSPA8, HDAC1 | More | | Bexarotene | hsa04217 | Necroptosis | 9.14E-03 | 7 | P01568, Q13489, P42224, Q6FI13, P10415, O43633, Q08752 | IFNA21, BIRC3, STAT1, H2AC18; H2AC19, BCL2, CHMP2A, PPID | More | | Bexarotene | hsa04261 | Adrenergic signaling in cardiomyocytes | 2.84E-02 | 5 | P09493, Q13362, P0DP23, P17252, P10415 | TPM1, PPP2R5C, CALM1, PRKCA, BCL2 | More | | Bexarotene | hsa04330 | Notch signaling pathway | 2.77E-02 | 2 | Q92542, P49768 | NCSTN, PSEN1 | More | | Bexarotene | hsa04340 | Hedgehog signaling pathway | 3.46E-02 | 4 | P49841, P22694, Q13635, P10415 | GSK3B, PRKACB, PTCH1, BCL2 | More | | Bexarotene | hsa04360 | Axon guidance | 4.04E-02 | 6 | P16333, P20827, O95631, P42338, P07332, P19174 | NCK1, EFNA1, NTN1, PIK3CB, FES, PLCG1 | More | | Bexarotene | hsa04370 | VEGF signaling pathway | 1.43E-05 | 3 | P16298, Q05397, Q02750 | PPP3CB, PTK2, MAP2K1 | More | | Bexarotene | hsa04371 | Apelin signaling pathway | 1.00E-02 | 7 | P63218, P50151, Q8WYR1, Q14814, Q14344, Q13485, P84022 | GNG5, GNG10, PIK3R5, MEF2D, GNA13, SMAD4, SMAD3 | More | | Bexarotene | hsa04512 | ECM-receptor interaction | 3.73E-02 | 2 | P07359, P08514 | GP1BA, ITGA2B | More | | Bexarotene | hsa04514 | Cell adhesion molecules | 8.19E-03 | 3 | P16109, P56750, O00501 | SELP, CLDN17, CLDN5 | More | | Bexarotene | hsa04530 | Tight junction | 1.38E-04 | 5 | Q8TEU7, P16989, P56750, O00501, Q14247 | RAPGEF6, CSDA, CLDN17, CLDN5, CTTN | More | | Bexarotene | hsa04540 | Gap junction | 1.29E-02 | 4 | P17252, Q13509, P68371, Q14643 | PRKCA, TUBB3, TUBB2C, ITPR1 | More | | Bexarotene | hsa04610 | Complement and coagulation cascades | 1.21E-03 | 3 | P25116, P09871, P0C0L4 | F2R, C1S, C4A | More | | Bexarotene | hsa04611 | Platelet activation | 5.18E-05 | 5 | P25116, P08514, Q15746, Q8WYR1, P07359 | F2R, ITGA2B, MYLK, PIK3R5, GP1BA | More | | Bexarotene | hsa04612 | Antigen processing and presentation | 2.40E-02 | 8 | P13765, P48382, P26715, P26717, Q13241, O43908, P01732, P01375 | HLA-DOB, RFX5, KLRC1, KLRC2, KLRD1, KLRC4, CD8A, TNF | More | | Bexarotene | hsa04613 | Neutrophil extracellular trap formation | 3.60E-05 | 20 | P17252, P16109, O60603, P05164, P08246, Q9UM07, Q6FI13, O60814, P68431, P14598, Q15080, P20160, P08311, O75015, P21730, P08514, P21462, P07359, O43315, Q16539 | PRKCA, SELP, TLR2, MPO, ELA2, PADI4, H2AC18; H2AC19, H2BC12, H3C1; H3C2; H3C3; H3C4; H3C6; H3C7; H3C8; H3C10; H3C11; H3C12, NCF1, NCF4, AZU1, CTSG, FCGR3B, C5AR1, ITGA2B, FPR1, GP1BA, AQP9, MAPK14 | More | Genes in community(ComG) | Gene name of ComG | Protein name of ComG | Co-expressed genes in pathway (PathG) | Gene name of PathG | Protein name of PathG | Coexpression |
---|
P17252 | PRKCA | Protein kinase C alpha type | P17252 | PRKCA | Protein kinase C alpha type | 1 | Q15722 | LTB4R | Leukotriene B4 receptor 1 | P17252 | PRKCA | Protein kinase C alpha type | -0.757 | P18054 | ALOX12 | Polyunsaturated fatty acid lipoxygenase ALOX12 | P16109 | SELP | P-selectin | 0.819 | P17252 | PRKCA | Protein kinase C alpha type | O60603 | TLR2 | Toll-like receptor 2 | -0.716 | P14780 | MMP9 | Matrix metalloproteinase-9 | O60603 | TLR2 | Toll-like receptor 2 | 0.89 | Q15722 | LTB4R | Leukotriene B4 receptor 1 | O60603 | TLR2 | Toll-like receptor 2 | 0.942 | P14780 | MMP9 | Matrix metalloproteinase-9 | P05164 | MPO | Myeloperoxidase | 0.812 | Q15722 | LTB4R | Leukotriene B4 receptor 1 | P05164 | MPO | Myeloperoxidase | 0.805 | P17252 | PRKCA | Protein kinase C alpha type | P08246 | ELA2 | Neutrophil elastase | -0.735 | P14780 | MMP9 | Matrix metalloproteinase-9 | P08246 | ELA2 | Neutrophil elastase | 0.859 | Q15722 | LTB4R | Leukotriene B4 receptor 1 | P08246 | ELA2 | Neutrophil elastase | 0.846 | P14780 | MMP9 | Matrix metalloproteinase-9 | Q9UM07 | PADI4 | Protein-arginine deiminase type-4 | 0.9 | Q15722 | LTB4R | Leukotriene B4 receptor 1 | Q9UM07 | PADI4 | Protein-arginine deiminase type-4 | 0.799 | P17252 | PRKCA | Protein kinase C alpha type | Q6FI13 | H2AC18; H2AC19 | Histone H2A type 2-A | -0.83 | P14780 | MMP9 | Matrix metalloproteinase-9 | Q6FI13 | H2AC18; H2AC19 | Histone H2A type 2-A | 0.74 | Q15722 | LTB4R | Leukotriene B4 receptor 1 | Q6FI13 | H2AC18; H2AC19 | Histone H2A type 2-A | 0.833 | P18054 | ALOX12 | Polyunsaturated fatty acid lipoxygenase ALOX12 | O60814 | H2BC12 | Histone H2B type 1-K | 0.783 | P17252 | PRKCA | Protein kinase C alpha type | P68431 | H3C1; H3C2; H3C3; H3C4; H3C6; H3C7; H3C8; H3C10; H3C11; H3C12 | Histone H3.1 | 0.783 | P17252 | PRKCA | Protein kinase C alpha type | P14598 | NCF1 | Neutrophil cytosol factor 1 | -0.821 | P17252 | PRKCA | Protein kinase C alpha type | Q15080 | NCF4 | Neutrophil cytosol factor 4 | -0.836 | P14780 | MMP9 | Matrix metalloproteinase-9 | Q15080 | NCF4 | Neutrophil cytosol factor 4 | 0.869 | Q15722 | LTB4R | Leukotriene B4 receptor 1 | Q15080 | NCF4 | Neutrophil cytosol factor 4 | 0.918 | P14780 | MMP9 | Matrix metalloproteinase-9 | P20160 | AZU1 | Azurocidin | 0.734 | P14780 | MMP9 | Matrix metalloproteinase-9 | P08311 | CTSG | Cathepsin G | 0.79 | P14780 | MMP9 | Matrix metalloproteinase-9 | O75015 | FCGR3B | Low affinity immunoglobulin gamma Fc region receptor III-B | 0.928 | Q15722 | LTB4R | Leukotriene B4 receptor 1 | O75015 | FCGR3B | Low affinity immunoglobulin gamma Fc region receptor III-B | 0.737 | P14780 | MMP9 | Matrix metalloproteinase-9 | P21730 | C5AR1 | C5a anaphylatoxin chemotactic receptor 1 | 0.942 | Q15722 | LTB4R | Leukotriene B4 receptor 1 | P21730 | C5AR1 | C5a anaphylatoxin chemotactic receptor 1 | 0.875 | P18054 | ALOX12 | Polyunsaturated fatty acid lipoxygenase ALOX12 | P08514 | ITGA2B | Integrin alpha-IIb | 0.941 | P17252 | PRKCA | Protein kinase C alpha type | P21462 | FPR1 | fMet-Leu-Phe receptor | -0.731 | P14780 | MMP9 | Matrix metalloproteinase-9 | P21462 | FPR1 | fMet-Leu-Phe receptor | 0.912 | Q15722 | LTB4R | Leukotriene B4 receptor 1 | P21462 | FPR1 | fMet-Leu-Phe receptor | 0.888 | P18054 | ALOX12 | Polyunsaturated fatty acid lipoxygenase ALOX12 | P07359 | GP1BA | Platelet glycoprotein Ib alpha chain | 0.876 | P14780 | MMP9 | Matrix metalloproteinase-9 | O43315 | AQP9 | Aquaporin-9 | 0.837 | Q15722 | LTB4R | Leukotriene B4 receptor 1 | O43315 | AQP9 | Aquaporin-9 | 0.79 | P14780 | MMP9 | Matrix metalloproteinase-9 | Q16539 | MAPK14 | Mitogen-activated protein kinase 14 | 0.778 | Q15722 | LTB4R | Leukotriene B4 receptor 1 | Q16539 | MAPK14 | Mitogen-activated protein kinase 14 | 0.721 |
| Bexarotene | hsa04621 | NOD-like receptor signaling pathway | 2.50E-03 | 12 | Q16539, Q14643, P21796, P10599, Q9H1Y0, P43490, O00463, P10415, Q05823, P01375, P09341, P12838 | MAPK14, ITPR1, VDAC1, TXN, ATG5, PBEF1, TRAF5, BCL2, RNASEL, TNF, CXCL1, DEFA4 | More | | Bexarotene | hsa04622 | RIG-I-like receptor signaling pathway | 2.47E-02 | 1 | Q12933 | TRAF2 | More | | Bexarotene | hsa04640 | Hematopoietic cell lineage | 1.37E-02 | 7 | P14778, P27930, P11215, P25063, P07766, P01732, P09564 | IL1R1, IL1R2, ITGAM, CD24, CD3E, CD8A, CD7 | More | | Bexarotene | hsa04650 | Natural killer cell mediated cytotoxicity | 4.85E-07 | 16 | P16298, P50591, P19174, P01375, P78314, P06239, O60880, P20963, P42338, Q02750, Q13241, P26718, O14931, O75015, P26717, P26715 | PPP3CB, TNFSF10, PLCG1, TNF, SH3BP2, LCK, SH2D1A, CD247, PIK3CB, MAP2K1, KLRD1, KLRK1, NCR3, FCGR3B, KLRC2, KLRC1 | More | | Bexarotene | hsa04657 | IL-17 signaling pathway | 5.02E-03 | 7 | O00463, Q16539, P49841, P09341, P14780, P80188, P01375 | TRAF5, MAPK14, GSK3B, CXCL1, MMP9, LCN2, TNF | More | | Bexarotene | hsa04658 | Th1 and Th2 cell differentiation | 9.90E-10 | 15 | Q04759, P07766, P20963, P09693, Q16539, P19174, P01730, P06239, P42224, Q14765, P23771, Q9UL17, P14784, P13765, Q13761 | PRKCQ, CD3E, CD247, CD3G, MAPK14, PLCG1, CD4, LCK, STAT1, STAT4, GATA3, TBX21, IL2RB, HLA-DOB, RUNX3 | More | | Bexarotene | hsa04659 | Th17 cell differentiation | 4.51E-08 | 13 | Q04759, P19174, P01730, P06239, P42224, P14784, P14778, Q9UL17, P84022, Q13485, P08238, P07766, P20963 | PRKCQ, PLCG1, CD4, LCK, STAT1, IL2RB, IL1R1, TBX21, SMAD3, SMAD4, HSP90AB1, CD3E, CD247 | More | | Bexarotene | hsa04660 | T cell receptor signaling pathway | 7.99E-06 | 17 | P01375, Q9UDY8, Q04759, P42338, O95267, Q08881, P19174, P16333, P07766, P20963, P09693, P01730, P01732, Q13191, P06239, Q16539, P49841 | TNF, MALT1, PRKCQ, PIK3CB, RASGRP1, ITK, PLCG1, NCK1, CD3E, CD247, CD3G, CD4, CD8A, CBLB, LCK, MAPK14, GSK3B | More | | Bexarotene | hsa04662 | B cell receptor signaling pathway | 1.00E-03 | 5 | P42338, P60033, P07948, P21854, Q8N149 | PIK3CB, CD81, LYN, CD72, LILRA2 | More | | Bexarotene | hsa04664 | Fc epsilon RI signaling pathway | 2.47E-02 | 4 | P42338, P07948, P19174, P09917 | PIK3CB, LYN, PLCG1, ALOX5 | More | | Bexarotene | hsa04672 | Intestinal immune network for IgA production | 3.76E-03 | 3 | P29965, P10747, P13765 | CD40LG, CD28, HLA-DOB | More | | Bexarotene | hsa04710 | Circadian rhythm | 1.67E-02 | 2 | Q16526, Q9Y478 | CRY1, PRKAB1 | More | | Bexarotene | hsa04713 | Circadian entrainment | 2.60E-02 | 4 | P0DP23, P17252, P62873, Q14643 | CALM1, PRKCA, GNB1, ITPR1 | More | | Bexarotene | hsa04720 | Long-term potentiation | 1.34E-04 | 6 | P17252, P16298, P0DP23, P51812, Q02750, Q14643 | PRKCA, PPP3CB, CALM1, RPS6KA3, MAP2K1, ITPR1 | More | | Bexarotene | hsa04723 | Retrograde endocannabinoid signaling | 8.76E-04 | 6 | Q14643, P17252, P62873, P22694, Q16539, Q16718 | ITPR1, PRKCA, GNB1, PRKACB, MAPK14, NDUFA5 | More | | Bexarotene | hsa04725 | Cholinergic synapse | 1.88E-02 | 4 | Q14643, P17252, P62873, P10415 | ITPR1, PRKCA, GNB1, BCL2 | More | | Bexarotene | hsa04727 | GABAergic synapse | 2.62E-02 | 3 | P63218, P50151, P15104 | GNG5, GNG10, GLUL | More | | Bexarotene | hsa04728 | Dopaminergic synapse | 3.55E-02 | 5 | Q14643, P17252, P62873, Q13362, P0DP23 | ITPR1, PRKCA, GNB1, PPP2R5C, CALM1 | More | | Bexarotene | hsa04730 | Long-term depression | 4.05E-02 | 2 | Q14344, P07948 | GNA13, LYN | More | | Bexarotene | hsa04744 | Phototransduction | 1.02E-02 | 2 | P62873, P0DP23 | GNB1, CALM1 | More | | Bexarotene | hsa04750 | Inflammatory mediator regulation of TRP channels | 7.24E-03 | 5 | P14778, P19174, P42338, P24723, Q04759 | IL1R1, PLCG1, PIK3CB, PRKCH, PRKCQ | More | | Bexarotene | hsa04810 | Regulation of actin cytoskeleton | 2.58E-02 | 3 | Q15746, P08514, P25116 | MYLK, ITGA2B, F2R | More | | Bexarotene | hsa04912 | GnRH signaling pathway | 3.31E-04 | 6 | P17252, Q16539, Q9Y6R4, Q14643, P0DP23, P22694 | PRKCA, MAPK14, MAP3K4, ITPR1, CALM1, PRKACB | More | | Bexarotene | hsa04914 | Progesterone-mediated oocyte maturation | 5.67E-04 | 4 | Q17RY0, Q9Y6D9, P51812, Q02750 | CPEB4, MAD1L1, RPS6KA3, MAP2K1 | More | | Bexarotene | hsa04920 | Adipocytokine signaling pathway | 4.31E-02 | 2 | Q9Y478, Q96RR4 | PRKAB1, CAMKK2 | More | | Bexarotene | hsa04922 | Glucagon signaling pathway | 3.47E-02 | 4 | Q12778, Q13370, P0DP23, Q14643 | FOXO1, PDE3B, CALM1, ITPR1 | More | | Bexarotene | hsa04923 | Regulation of lipolysis in adipocytes | 2.24E-02 | 3 | P07550, P42338, Q9Y4H2 | ADRB2, PIK3CB, IRS2 | More | | Bexarotene | hsa04924 | Renin secretion | 8.71E-03 | 3 | Q14643, Q13370, P0DP23 | ITPR1, PDE3B, CALM1 | More | | Bexarotene | hsa04928 | Parathyroid hormone synthesis, secretion and action | 3.75E-02 | 5 | Q14643, P22694, P23771, P17252, P10415 | ITPR1, PRKACB, GATA3, PRKCA, BCL2 | More | | Bexarotene | hsa04930 | Type II diabetes mellitus | 2.47E-02 | 1 | Q02156 | PRKCE | More | | Bexarotene | hsa04933 | AGE-RAGE signaling pathway in diabetic complications | 1.19E-03 | 9 | P84022, Q13485, P42224, P10415, P42338, Q12778, P49767, P17252, P19174 | SMAD3, SMAD4, STAT1, BCL2, PIK3CB, FOXO1, VEGFC, PRKCA, PLCG1 | More | | Bexarotene | hsa04966 | Collecting duct acid secretion | 2.86E-02 | 2 | Q13488, Q9Y666 | TCIRG1, SLC12A7 | More | | Bexarotene | hsa04973 | Carbohydrate digestion and absorption | 1.29E-02 | 2 | O43451, P42338 | MGAM, PIK3CB | More | | Bexarotene | hsa04974 | Protein digestion and absorption | 2.47E-02 | 1 | Q7Z2H8 | SLC36A1 | More | | Bexarotene | hsa05010 | Alzheimer disease | 3.55E-02 | 7 | Q16718, O14521, Q14643, P0DP23, Q13509, P68371, Q08752 | NDUFA5, SDHD, ITPR1, CALM1, TUBB3, TUBB2C, PPID | More | | Bexarotene | hsa05012 | Parkinson disease | 2.25E-02 | 6 | Q16718, O14521, Q14643, P0DP23, Q13509, P68371 | NDUFA5, SDHD, ITPR1, CALM1, TUBB3, TUBB2C | More | | Bexarotene | hsa05016 | Huntington disease | 1.07E-02 | 3 | Q9GZM3, P52435, P55036 | POLR2J2, POLR2J, PSMD4 | More | | Bexarotene | hsa05020 | Prion disease | 1.15E-02 | 7 | Q16718, O14521, Q14643, Q13509, P68371, P14598, Q15080 | NDUFA5, SDHD, ITPR1, TUBB3, TUBB2C, NCF1, NCF4 | More | | Bexarotene | hsa05022 | Pathways of neurodegeneration - multiple diseases | 4.48E-03 | 10 | Q14643, Q13509, P68371, P10415, Q16718, O14521, Q13561, P17252, Q08752, P0DP23 | ITPR1, TUBB3, TUBB2C, BCL2, NDUFA5, SDHD, DCTN2, PRKCA, PPID, CALM1 | More | | Bexarotene | hsa05120 | Epithelial cell signaling in Helicobacter pylori infection | 2.84E-05 | 7 | Q16539, P09341, P19875, P19174, P25024, P25025, P07948 | MAPK14, CXCL1, CXCL2, PLCG1, CXCR1, CXCR2, LYN | More | | Bexarotene | hsa05130 | Pathogenic Escherichia coli infection | 7.39E-03 | 4 | Q14247, P56750, O00501, P25116 | CTTN, CLDN17, CLDN5, F2R | More | | Bexarotene | hsa05131 | Shigellosis | 3.33E-03 | 10 | Q12933, P68431, Q02156, Q9UDY8, Q14247, Q14643, Q12778, Q13315, P10415, Q08752 | TRAF2, H3C1; H3C2; H3C3; H3C4; H3C6; H3C7; H3C8; H3C10; H3C11; H3C12, PRKCE, MALT1, CTTN, ITPR1, FOXO1, ATM, BCL2, PPID | More | | Bexarotene | hsa05132 | Salmonella infection | 1.11E-02 | 8 | Q9UJU2, Q13489, P10415, O60603, Q9BQS8, Q13561, Q13509, P68371 | LEF1, BIRC3, BCL2, TLR2, FYCO1, DCTN2, TUBB3, TUBB2C | More | | Bexarotene | hsa05133 | Pertussis | 2.18E-03 | 3 | P09871, P0C0L4, Q02556 | C1S, C4A, IRF8 | More | | Bexarotene | hsa05134 | Legionellosis | 1.29E-02 | 4 | P11215, P11142, P09341, P19875 | ITGAM, HSPA8, CXCL1, CXCL2 | More | | Bexarotene | hsa05135 | Yersinia infection | 2.58E-02 | 4 | Q05397, P51812, Q02750, Q96JJ3 | PTK2, RPS6KA3, MAP2K1, ELMO2 | More | | Bexarotene | hsa05140 | Leishmaniasis | 1.61E-05 | 11 | P13612, O75015, P14598, P42224, P13765, O60603, P01375, P29350, P49006, Q16539, Q15080 | ITGA4, FCGR3B, NCF1, STAT1, HLA-DOB, TLR2, TNF, PTPN6, MARCKSL1, MAPK14, NCF4 | More | | Bexarotene | hsa05145 | Toxoplasmosis | 1.11E-02 | 6 | P10415, Q13489, P42224, P13765, O60603, P29965 | BCL2, BIRC3, STAT1, HLA-DOB, TLR2, CD40LG | More | | Bexarotene | hsa05146 | Amoebiasis | 1.22E-05 | 12 | P09341, P19875, P14778, P27930, P01375, O60603, P42338, P11215, P05089, P22694, P12814, P08311 | CXCL1, CXCL2, IL1R1, IL1R2, TNF, TLR2, PIK3CB, ITGAM, ARG1, PRKACB, ACTN1, CTSG | More | | Bexarotene | hsa05152 | Tuberculosis | 4.68E-05 | 11 | Q13488, P0DP23, O75015, P42224, P48382, O60603, P10415, P13765, P01568, Q9UDY8, Q16539 | TCIRG1, CALM1, FCGR3B, STAT1, RFX5, TLR2, BCL2, HLA-DOB, IFNA21, MALT1, MAPK14 | More | | Bexarotene | hsa05163 | Human cytomegalovirus infection | 4.21E-04 | 12 | P01375, P63218, P50151, Q14643, Q14344, P49841, P14778, P25025, Q16539, P04637, O00463, P30101 | TNF, GNG5, GNG10, ITPR1, GNA13, GSK3B, IL1R1, CXCR2, MAPK14, TP53, TRAF5, PDIA3 | More | | Bexarotene | hsa05165 | Human papillomavirus infection | 3.10E-02 | 8 | P16144, Q05086, P01568, P42224, Q13488, Q13362, Q12778, Q13315 | ITGB4, UBE3A, IFNA21, STAT1, TCIRG1, PPP2R5C, FOXO1, ATM | More | | Bexarotene | hsa05167 | Kaposi sarcoma-associated herpesvirus infection | 3.04E-03 | 10 | P01568, P42224, P62873, P62879, P16298, Q14643, Q02750, P0DP23, P0CG47, Q9UJU2 | IFNA21, STAT1, GNB1, GNB2, PPP3CB, ITPR1, MAP2K1, CALM1, UBB, LEF1 | More | | Bexarotene | hsa05170 | Human immunodeficiency virus 1 infection | 1.09E-05 | 14 | Q02750, P62873, P62879, P16298, P0DP23, Q05397, P17252, Q14643, P01568, O60603, Q13315, P10415, Q9Y6Q5, P20333 | MAP2K1, GNB1, GNB2, PPP3CB, CALM1, PTK2, PRKCA, ITPR1, IFNA21, TLR2, ATM, BCL2, AP1M2, TNFRSF1B | More | | Bexarotene | hsa05200 | Pathways in cancer | 1.55E-03 | 28 | Q13751, P42338, P08238, P42224, P19174, Q9UJU2, P17252, P43246, P84022, Q13485, Q13547, P14923, P30281, P10415, Q13489, P49767, Q12778, P43657, P25116, P62873, P63218, P50151, Q14344, Q7LDG7, O75293, P0DP23, P01568, P14784 | LAMB3, PIK3CB, HSP90AB1, STAT1, PLCG1, LEF1, PRKCA, MSH2, SMAD3, SMAD4, HDAC1, JUP, CCND3, BCL2, BIRC3, VEGFC, FOXO1, P2RY5, F2R, GNB1, GNG5, GNG10, GNA13, RASGRP2, GADD45B, CALM1, IFNA21, IL2RB | More | Genes in community(ComG) | Gene name of ComG | Protein name of ComG | Co-expressed genes in pathway (PathG) | Gene name of PathG | Protein name of PathG | Coexpression |
---|
P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | Q13751 | LAMB3 | Laminin subunit beta-3 | 0.844 | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | P42338 | PIK3CB | Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit beta isoform | 0.777 | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | P08238 | HSP90AB1 | Heat shock protein HSP 90-beta | -0.823 | P17252 | PRKCA | Protein kinase C alpha type | P42224 | STAT1 | Signal transducer and activator of transcription 1-alpha/beta | -0.706 | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | P19174 | PLCG1 | 1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase gamma-1 | -0.766 | P17252 | PRKCA | Protein kinase C alpha type | Q9UJU2 | LEF1 | Lymphoid enhancer-binding factor 1 | 0.881 | P17252 | PRKCA | Protein kinase C alpha type | P17252 | PRKCA | Protein kinase C alpha type | 1 | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | P43246 | MSH2 | DNA mismatch repair protein Msh2 | -0.811 | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | P84022 | SMAD3 | Mothers against decapentaplegic homolog 3 | 0.725 | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | Q13485 | SMAD4 | Mothers against decapentaplegic homolog 4 | -0.746 | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | Q13547 | HDAC1 | Histone deacetylase 1 | -0.754 | P17252 | PRKCA | Protein kinase C alpha type | P14923 | JUP | Junction plakoglobin | 0.761 | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | P30281 | CCND3 | G1/S-specific cyclin-D3 | 0.743 | P17252 | PRKCA | Protein kinase C alpha type | P10415 | BCL2 | Apoptosis regulator Bcl-2 | 0.844 | P17252 | PRKCA | Protein kinase C alpha type | Q13489 | BIRC3 | Baculoviral IAP repeat-containing protein 3 | 0.849 | P17252 | PRKCA | Protein kinase C alpha type | P49767 | VEGFC | Vascular endothelial growth factor C | 0.719 | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | P49767 | VEGFC | Vascular endothelial growth factor C | 0.743 | P17252 | PRKCA | Protein kinase C alpha type | Q12778 | FOXO1 | Forkhead box protein O1 | 0.863 | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | P43657 | P2RY5 | Lysophosphatidic acid receptor 6 | -0.735 | P17252 | PRKCA | Protein kinase C alpha type | P25116 | F2R | Proteinase-activated receptor 1 | 0.857 | P17252 | PRKCA | Protein kinase C alpha type | P62873 | GNB1 | Guanine nucleotide-binding protein G(I)/G(S)/G(T) subunit beta-1 | -0.852 | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | P63218 | GNG5 | Guanine nucleotide-binding protein G(I)/G(S)/G(O) subunit gamma-5 | 0.941 | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | P50151 | GNG10 | Guanine nucleotide-binding protein G(I)/G(S)/G(O) subunit gamma-10 | 0.948 | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | Q14344 | GNA13 | Guanine nucleotide-binding protein subunit alpha-13 | 0.87 | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | Q7LDG7 | RASGRP2 | RAS guanyl-releasing protein 2 | 0.704 | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | O75293 | GADD45B | Growth arrest and DNA damage-inducible protein GADD45 beta | 0.731 | P17252 | PRKCA | Protein kinase C alpha type | P0DP23 | CALM1 | Calmodulin-1 | -0.776 | P17252 | PRKCA | Protein kinase C alpha type | P01568 | IFNA21 | Interferon alpha-21 | 0.733 | P09917 | ALOX5 | Polyunsaturated fatty acid 5-lipoxygenase | P14784 | IL2RB | Interleukin-2 receptor subunit beta | -0.835 |
| Bexarotene | hsa05202 | Transcriptional misregulation in cancer | 3.44E-04 | 18 | Q12778, Q15532, P41732, P14780, P27930, Q15744, Q16548, Q13489, Q13077, O15550, P35226, P05164, P12838, P08246, Q9C0K0, P41182, P12980, P24522 | FOXO1, SS18, TSPAN7, MMP9, IL1R2, CEBPE, BCL2A1, BIRC3, TRAF1, UTX, BMI1, MPO, DEFA4, ELA2, BCL11B, BCL6, LYL1, GADD45A | More | | Bexarotene | hsa05212 | Pancreatic cancer | 3.94E-02 | 4 | P42338, P84022, Q13485, O75293 | PIK3CB, SMAD3, SMAD4, GADD45B | More | | Bexarotene | hsa05213 | Endometrial cancer | 3.79E-02 | 2 | O15169, Q02750 | AXIN1, MAP2K1 | More | | Bexarotene | hsa05219 | Bladder cancer | 4.07E-02 | 2 | P14780, P04637 | MMP9, TP53 | More | | Bexarotene | hsa05220 | Chronic myeloid leukemia | 2.16E-02 | 5 | Q13547, Q13485, P84022, P42338, O75293 | HDAC1, SMAD4, SMAD3, PIK3CB, GADD45B | More | | Bexarotene | hsa05223 | Non-small cell lung cancer | 4.24E-02 | 3 | P19174, Q9HC35, O75293 | PLCG1, EML4, GADD45B | More | | Bexarotene | hsa05224 | Breast cancer | 4.75E-02 | 4 | P49841, Q92837, P04637, P24522 | GSK3B, FRAT1, TP53, GADD45A | More | | Bexarotene | hsa05226 | Gastric cancer | 3.79E-02 | 2 | Q02750, O15169 | MAP2K1, AXIN1 | More | | Bexarotene | hsa05231 | Choline metabolism in cancer | 4.24E-02 | 3 | Q9Y259, P19174, P49619 | CHKB, PLCG1, DGKG | More | | Bexarotene | hsa05235 | PD-L1 expression and PD-1 checkpoint pathway in cancer | 8.76E-06 | 13 | P42338, O95267, P19174, P07766, P20963, P09693, P06239, P42224, O60603, Q04759, Q16539, Q9HC35, P01730 | PIK3CB, RASGRP1, PLCG1, CD3E, CD247, CD3G, LCK, STAT1, TLR2, PRKCQ, MAPK14, EML4, CD4 | More | | Bexarotene | hsa05310 | Asthma | 2.81E-02 | 3 | P13765, P12724, P01375 | HLA-DOB, RNASE3, TNF | More | | Bexarotene | hsa05320 | Autoimmune thyroid disease | 1.27E-03 | 4 | P13765, P29965, P01568, P10747 | HLA-DOB, CD40LG, IFNA21, CD28 | More | | Bexarotene | hsa05321 | Inflammatory bowel disease | 3.31E-04 | 6 | O60603, P01375, P13765, Q14765, Q9UL17, P23771 | TLR2, TNF, HLA-DOB, STAT4, TBX21, GATA3 | More | | Bexarotene | hsa05322 | Systemic lupus erythematosus | 4.18E-03 | 7 | P08246, P09871, P10747, P13765, P29965, Q6FI13, P68431 | ELA2, C1S, CD28, HLA-DOB, CD40LG, H2AC18; H2AC19, H3C1; H3C2; H3C3; H3C4; H3C6; H3C7; H3C8; H3C10; H3C11; H3C12 | More | | Bexarotene | hsa05323 | Rheumatoid arthritis | 1.29E-02 | 4 | P13765, Q13488, P10747, O60603 | HLA-DOB, TCIRG1, CD28, TLR2 | More | | Bexarotene | hsa05330 | Allograft rejection | 1.62E-02 | 3 | P13765, P29965, P10747 | HLA-DOB, CD40LG, CD28 | More | | Bexarotene | hsa05332 | Graft-versus-host disease | 1.07E-03 | 5 | P13765, P10747, P01375, P26715, Q13241 | HLA-DOB, CD28, TNF, KLRC1, KLRD1 | More | | Bexarotene | hsa05340 | Primary immunodeficiency | 4.85E-03 | 3 | P01730, P07766, P06239 | CD4, CD3E, LCK | More | | Bexarotene | hsa05415 | Diabetic cardiomyopathy | 3.55E-02 | 5 | P17252, P14598, Q15080, Q16718, O14521 | PRKCA, NCF1, NCF4, NDUFA5, SDHD | More | | Bexarotene | hsa05416 | Viral myocarditis | 2.62E-02 | 3 | P13765, P29965, P10747 | HLA-DOB, CD40LG, CD28 | More | | Bexarotene | hsa05418 | Fluid shear stress and atherosclerosis | 2.62E-02 | 6 | Q16539, P10599, P14780, P04637, P14778, P27930 | MAPK14, TXN, MMP9, TP53, IL1R1, IL1R2 | More | | |